Literature DB >> 24371231

Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer.

Fernando J de Miguel1, Ravi D Sharma, María J Pajares, Luis M Montuenga, Angel Rubio, Ruben Pio.   

Abstract

Abnormal alternative splicing has been associated with cancer. Genome-wide microarrays can be used to detect differential splicing events. In this study, we have developed ExonPointer, an algorithm that uses data from exon and junction probes to identify annotated cassette exons. We used the algorithm to profile differential splicing events in lung adenocarcinoma A549 cells after downregulation of the oncogenic serine/arginine-rich splicing factor 1 (SRSF1). Data were generated using two different microarray platforms. The PCR-based validation rate of the top 20 ranked genes was 60% and 100%. Functional enrichment analyses found a substantial number of splicing events in genes related to RNA metabolism. These analyses also identified genes associated with cancer and developmental and hereditary disorders, as well as biologic processes such as cell division, apoptosis, and proliferation. Most of the top 20 ranked genes were validated in other adenocarcinoma and squamous cell lung cancer cells, with validation rates of 80% to 95% and 70% to 75%, respectively. Moreover, the analysis allowed us to identify four genes, ATP11C, IQCB1, TUBD1, and proline-rich coiled-coil 2C (PRRC2C), with a significantly different pattern of alternative splicing in primary non-small cell lung tumors compared with normal lung tissue. In the case of PRRC2C, SRSF1 downregulation led to the skipping of an exon overexpressed in primary lung tumors. Specific siRNA downregulation of the exon-containing variant significantly reduced cell growth. In conclusion, using a novel analytical tool, we have identified new splicing events regulated by the oncogenic splicing factor SRSF1 in lung cancer. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24371231     DOI: 10.1158/0008-5472.CAN-13-1481

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

Review 1.  Genome-wide analysis of microRNA and mRNA expression signatures in cancer.

Authors:  Ming-hui Li; Sheng-bo Fu; Hua-sheng Xiao
Journal:  Acta Pharmacol Sin       Date:  2015-08-24       Impact factor: 6.150

2.  SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia.

Authors:  Joanna R Sinnakannu; Kian Leong Lee; Shanshan Cheng; Jia Li; Mengge Yu; Siew Peng Tan; Clara Chong Hui Ong; Huihua Li; Hein Than; Olga Anczuków-Camarda; Adrian R Krainer; Xavier Roca; Steven G Rozen; Jabed Iqbal; Henry Yang; Charles Chuah; Sin Tiong Ong
Journal:  Leukemia       Date:  2020-02-12       Impact factor: 11.528

3.  A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer.

Authors:  Fernando J de Miguel; María J Pajares; Elena Martínez-Terroba; Daniel Ajona; Xabier Morales; Ravi D Sharma; Francisco J Pardo; Ana Rouzaut; Angel Rubio; Luis M Montuenga; Ruben Pio
Journal:  Mol Oncol       Date:  2016-08-09       Impact factor: 6.603

4.  Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B.

Authors:  Xuexia Zhou; Run Wang; Xuebing Li; Lin Yu; Dan Hua; Cuiyun Sun; Cuijuan Shi; Wenjun Luo; Chun Rao; Zhendong Jiang; Ying Feng; Qian Wang; Shizhu Yu
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

5.  The aberrant splicing of BAF45d links splicing regulation and transcription in glioblastoma.

Authors:  Guillermo Aldave; Marisol Gonzalez-Huarriz; Angel Rubio; Juan Pablo Romero; Datta Ravi; Belén Miñana; Mar Cuadrado-Tejedor; Ana García-Osta; Roeland Verhaak; Enric Xipell; Naiara Martinez-Vélez; Arlet Acanda de la Rocha; Montserrat Puigdelloses; Marc García-Moure; Miguel Marigil; Jaime Gállego Pérez-Larraya; Oskar Marín-Bejar; Maite Huarte; Maria Stella Carro; Roberto Ferrarese; Cristobal Belda-Iniesta; Angel Ayuso; Ricardo Prat-Acín; Fernando Pastor; Ricardo Díez-Valle; Sonia Tejada; Marta M Alonso
Journal:  Neuro Oncol       Date:  2018-06-18       Impact factor: 12.300

6.  CLASS2: accurate and efficient splice variant annotation from RNA-seq reads.

Authors:  Li Song; Sarven Sabunciyan; Liliana Florea
Journal:  Nucleic Acids Res       Date:  2016-03-14       Impact factor: 16.971

7.  TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC.

Authors:  Jackeline Agorreta; Jianting Hu; Dongxia Liu; Domenico Delia; Helen Turley; David J P Ferguson; Francisco Iborra; María J Pajares; Marta Larrayoz; Isabel Zudaire; Ruben Pio; Luis M Montuenga; Adrian L Harris; Kevin Gatter; Francesco Pezzella
Journal:  Mol Cancer Res       Date:  2014-02-24       Impact factor: 5.852

8.  Splicing factor SRSF1 promotes breast cancer progression via oncogenic splice switching of PTPMT1.

Authors:  Jun-Xian Du; Yi-Hong Luo; Si-Jia Zhang; Biao Wang; Cong Chen; Gui-Qi Zhu; Ping Zhu; Cheng-Zhe Cai; Jing-Lei Wan; Jia-Liang Cai; Shi-Ping Chen; Zhi Dai; Wei Zhu
Journal:  J Exp Clin Cancer Res       Date:  2021-05-15

9.  AKT3-mediated IWS1 phosphorylation promotes the proliferation of EGFR-mutant lung adenocarcinomas through cell cycle-regulated U2AF2 RNA splicing.

Authors:  Georgios I Laliotis; Evangelia Chavdoula; Maria D Paraskevopoulou; Abdul Kaba; Alessandro La Ferlita; Satishkumar Singh; Vollter Anastas; Keith A Nair; Arturo Orlacchio; Vasiliki Taraslia; Ioannis Vlachos; Marina Capece; Artemis Hatzigeorgiou; Dario Palmieri; Christos Tsatsanis; Salvatore Alaimo; Lalit Sehgal; David P Carbone; Vincenzo Coppola; Philip N Tsichlis
Journal:  Nat Commun       Date:  2021-07-30       Impact factor: 14.919

10.  ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development.

Authors:  Haiqing He; Jun Hao; Xin Dong; Yu Wang; Hui Xue; Sifeng Qu; Stephen Yiu Chuen Choi; Xinpei Ci; Yong Wang; Rebecca Wu; Mingchen Shi; Xiaokun Zhao; Colin Collins; Dong Lin; Yuzhuo Wang
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-02-10       Impact factor: 5.554

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.